Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 in Chronic Cougher
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 Capsule as an Anti-Tussive Agent in Cough Patients: Double Blinded, Randomized, Placebo and Active Rug Comparative, Parallel Designed Phase III Study
Study Start Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adult between the ages of 18 and 70.
Patient who has cough symptom caused by following diseases: chronic bronchitis, bronchiectasis, gastroesophageal reflux disease, postnasal drip syndrome caused by rhinitis, sinusitis, rhinopharyngitis, rhinolaryngitis.
Patient requiring internal treatment due to cough symptom, who has coughing more than 3 weeks.
patient who will continue to cough more than 1 week.(by physician's judgment)
Patient who decided to participate in this clinical trial at his(her) own will and agreed in written letter of consent.
Patient who is trustworthy, ready for cooperation and observing the restrictions during the trial period.
Patient who is accompanied by the seriously abnormal symptom in respiratory system, such as Acute infectious Pulmonary Disease, Tuberculosis.
Patient who has clinical history of sensitivity to Xanthine drug.
Patient who has Peptic Ulcer or Asthma (Except Cicatrix)
Patient whose liver or kidney function is seriously abnormal: Including the cases of sGOT, sGPT, bilirubin and blood creatinine value exceeding twice of their upper normal limit.
Patient whose heart function is abnormal: including the case of showing abnormal EKG test value that is clinically significant.
Patient who has experience to have participated in other clinical trial within two months before starting the trial.
Pregnant woman, lactating woman.
patient who has convulsion or alcoholism.
patient who take medicines which can not use combination with AG1321001.